Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:MYOV

Myovant Sciences (MYOV) Stock Price, News & Analysis

Myovant Sciences logo

About Myovant Sciences Stock (NYSE:MYOV)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$26.98
$27.00
50-Day Range
$26.88
$26.99
52-Week Range
$7.67
$27.06
Volume
2.26 million shs
Average Volume
1.17 million shs
Market Capitalization
$2.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Remove Ads
Receive MYOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter.

MYOV Stock News Headlines

Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
See More Headlines

MYOV Stock Analysis - Frequently Asked Questions

Myovant Sciences Ltd. (NYSE:MYOV) announced its quarterly earnings results on Tuesday, October, 26th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.11. The business had revenue of $77.90 million for the quarter, compared to analyst estimates of $72.67 million.

Myovant Sciences (MYOV) raised $176 million in an IPO on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Myovant Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

Last Earnings
10/26/2021
Today
4/02/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSE:MYOV
Previous Symbol
NASDAQ:MYOV
Fax
N/A
Employees
407
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-205,980,000.00
Pretax Margin
-42.81%

Debt

Sales & Book Value

Annual Sales
$230.97 million
Price / Cash Flow
N/A
Book Value
($5.04) per share
Price / Book
-5.35

Miscellaneous

Free Float
95,388,000
Market Cap
$2.62 billion
Optionable
Not Optionable
Beta
2.17

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NYSE:MYOV) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners